预约演示
更新于：2026-01-12
Lanthanum carbonate
碳酸镧
更新于：2026-01-12
概要
基本信息
原研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2004-10-26), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式CH4LaO4 |
InChIKeyLIOPFGUJULMLEN-UHFFFAOYSA-N |
CAS号54451-24-0 |
关联
69
项与 碳酸镧 相关的临床试验EUCTR2019-003698-24-NL
Patient preference-based phosphate binder therapy in haemodialysis patients: a feasibility study on patient satisfaction
NCT04440696
To Evaluate the Tolerance, pd, and pk of Lanthanum Polystyrene-sulfonate Powder in a Phase Ib/ IIa Clinical Trial in Patients With ESRD-HD Hyperphosphatemia With Multi-center, Multi-dose, Give the Drug Multiple Time
NCT03451019
Effect of Lanthanum Carbonate and Sevelamer Hydrochloride on Gastrointestinal Calcium Absorption in Patients With Moderate to Advanced Chronic Kidney Disease
100 项与 碳酸镧 相关的临床结果
登录后查看更多信息
100 项与 碳酸镧 相关的转化医学
登录后查看更多信息
100 项与 碳酸镧 相关的专利（医药）
登录后查看更多信息
1,091
项与 碳酸镧 相关的文献（医药）2026-01-01INTERNAL MEDICINE
Association between Phosphate Binders and Constipation in Patients Undergoing Chronic Hemodialysis: A Cross-sectional Study
Article
作者: Morozumi, Kunio ; Takahashi, Hiroshi ; Kondo, Chika ; Hori, Mayuko ; Takeda, Asami ; Maruyama, Shoichi
Objective Constipation, a clinical form of gut dysbiosis, is highly prevalent in patients undergoing hemodialysis. Patients with chronic kidney disease experience uremia-related changes in the gut environment. Dysbiosis reportedly leads to an atherosclerosis pathogenesis, and constipation is associated with several adverse clinical outcomes including cardiovascular disease and mortality. Phosphate binders, commonly prescribed to patients with end-stage renal disease, bind to non-phosphate molecules and may alter the gut microbiota, potentially leading to systemic effects unrelated to phosphate control, although the clinical evidence is limited. Methods This cross-sectional study included 293 outpatients undergoing hemodialysis at Masuko Memorial Hospital, Japan. Information about patient characteristics and medication usage was collected, and constipation was assessed using the original diagnostic criteria, incorporating both the Rome IV criteria and a history of laxative use. Results Of 293 participants, 152 (51.9%) were diagnosed with constipation and 60 (20.5%) had severe constipation. Lanthanum carbonate use was independently associated with a lower risk of constipation (adjusted odds ratio [aOR] 0.55, 95% confidence interval [CI] 0.32-0.94, p=0.029) and a lower risk of severe constipation (aOR 0.41, 95%CI 0.19-0.86; p=0.018), while precipitated calcium carbonate use was associated with a lower risk of severe constipation, independent of age and sex (aOR 0.48, 95%CI 0.26-0.89, p=0.021). Conclusion Our study highlights the association between specific phosphate binders and a lower risk of constipation. Accordingly, phosphate binders could be selected based on their positive effects on constipation in this patient population.
2025-12-01INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY
Crystal-Storing Histiocytosis of the Duodenum in a Patient With IgG-Lambda Multiple Myeloma
Article
作者: Alipour, Zahra ; Yang, Zhaohai ; Koga, Shunsuke
Crystal-storing histiocytosis is a rare condition characterized by the accumulation of crystalline immunoglobulins within histiocytes, often associated with plasma cell disorders such as multiple myeloma. We report a 70-year-old man with a history of IgG-lambda multiple myeloma, systemic amyloidosis, and end-stage renal disease managed with peritoneal dialysis and long-term lanthanum carbonate therapy for hyperphosphatemia, who presented with gastrointestinal bleeding. Endoscopy revealed nodular erythematous mucosa in the duodenum, and biopsies showed histiocytosis in the lamina propria. The histiocytes showed abundant cytoplasm containing periodic acid–Schiff-positive diastase-resistant intracellular material. Immunohistochemical staining revealed diffuse CD68 positivity and lambda light-chain restriction of the storage material in the histiocytes, supporting a diagnosis of crystal-storing histiocytosis. Differential diagnoses, including Whipple disease, mycobacterial infections, lanthanum deposition, amyloidosis, and xanthoma, were excluded based on histological findings and clinical history. This report highlights the importance of recognizing crystal-storing histiocytosis in uncommon sites such as the duodenum, especially in the context of plasma cell dyscrasias.
2025-12-01AMERICAN JOURNAL OF CLINICAL NUTRITION
Lanthanum carbonate lowers serum phosphorus without altering body phosphorus burden in maintenance peritoneal dialysis patients: a randomized crossover trial
Article
作者: Shah, Anuja P ; Mehrotra, Rajnish ; Kopple, Joel D ; Ekramzadeh, Maryam ; Bross, Rachelle ; Lyzlov, Alex ; Lodebo, Bereket T ; Markovic, Daniela
BACKGROUND:
Many studies show that intestinal phosphate binders reduce serum phosphorus concentrations in hyperphosphatemic patients with chronic kidney failure. To our knowledge, there are virtually no studies of the effect of these binders on fecal phosphate or body phosphate.
OBJECTIVES:
This study examined the hypothesis that phosphate binders increase fecal phosphate and reduce body phosphorus burden.
METHODS:
Seven adult patients undergoing maintenance peritoneal dialysis underwent full metabolic balance studies for phosphorus in a research ward while they ate a constant phosphorus diet. Patients were studied during a baseline period without phosphate binders and while they received, in random order, 3 doses of lanthanum carbonate (La2(CO3)3), 1.5, 3.0, and 4.5 g/d, in 3 divided daily doses for ∼12-14 d each. The total duration of study was 47-49 d in each patient. Dialysate, urine, and feces were collected continuously and serum intermittently for phosphorus measurements.
RESULTS:
Serum phosphorus concentrations fell progressively and significantly as the La2(CO3)3 dose was increased (r = -0.47, P < 0.001). Fecal phosphorus concentrations rose progressively as La2(CO3)3 increased (r = 46.4, P < 0.001). However, there was a negative correlation between both dialysate (r = -17.2, P = 0.002) and urine (r = -18.5, P < 0.001) phosphorus and La2(CO3)3 dose. This decline in dialysate and urine phosphorus correlated with the fall in serum phosphorus concentration as the La2(CO3)3 dose increased. As the La2(CO3)3 dose rose, the increase in fecal phosphorus concentration was essentially counterbalanced by the fall in dialysate and urine phosphorus. Hence, body phosphorus balance did not change with increasing La2(CO3)3 doses.
CONCLUSIONS:
La2(CO3)3 treatment lowered serum phosphorus concentration but did not change body phosphorus content. This trial was registered at clinicaltrials.gov as NCT01581996.
100 项与 碳酸镧 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 高磷血症 | 奥地利 | 2005-03-01 | |
| 高磷血症 | 比利时 | 2005-03-01 | |
| 高磷血症 | 保加利亚 | 2005-03-01 | |
| 高磷血症 | 丹麦 | 2005-03-01 | |
| 高磷血症 | 爱沙尼亚 | 2005-03-01 | |
| 高磷血症 | 芬兰 | 2005-03-01 | |
| 高磷血症 | 法国 | 2005-03-01 | |
| 高磷血症 | 匈牙利 | 2005-03-01 | |
| 高磷血症 | 冰岛 | 2005-03-01 | |
| 高磷血症 | 爱尔兰 | 2005-03-01 | |
| 高磷血症 | 意大利 | 2005-03-01 | |
| 高磷血症 | 拉脱维亚 | 2005-03-01 | |
| 高磷血症 | 立陶宛 | 2005-03-01 | |
| 高磷血症 | 卢森堡 | 2005-03-01 | |
| 高磷血症 | 马耳他 | 2005-03-01 | |
| 高磷血症 | 荷兰 | 2005-03-01 | |
| 高磷血症 | 挪威 | 2005-03-01 | |
| 高磷血症 | 斯洛伐克 | 2005-03-01 | |
| 高磷血症 | 斯洛文尼亚 | 2005-03-01 | |
| 高磷血症 | 西班牙 | 2005-03-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 慢性肾病 serum phosphorus | oxidative stress | vascular dysfunction | 54 | 網壓憲醖繭鹽鏇糧鹹選(夢餘鹹鹽獵觸築觸觸淵) = 蓋範鏇襯齋繭製鏇齋襯 網繭構艱憲鑰憲積憲遞 (餘積淵鹹夢醖鑰餘窪遞 ) | 不佳 | 2024-05-23 | ||
Placebo | 網壓憲醖繭鹽鏇糧鹹選(夢餘鹹鹽獵觸築觸觸淵) = 鏇淵夢蓋膚膚廠夢鬱醖 網繭構艱憲鑰憲積憲遞 (餘積淵鹹夢醖鑰餘窪遞 ) | ||||||
临床2期 | 慢性肾病 interleukin-6 | C-reactive protein | 127 | 壓築積遞膚願餘繭繭餘(遞選衊遞築築獵簾窪選) = 遞糧顧鑰夢襯製獵觸製 憲廠壓範簾鑰築簾觸膚 (淵鹹鬱艱艱簾製積夢築 ) 更多 | 积极 | 2024-04-04 | ||
Placebo | 壓築積遞膚願餘繭繭餘(遞選衊遞築築獵簾窪選) = 繭壓構醖壓構艱鹹壓製 憲廠壓範簾鑰築簾觸膚 (淵鹹鬱艱艱簾製積夢築 ) 更多 | ||||||
临床1期 | - | 39 | (Lanthanum + Nicotinamide) | 餘願觸鑰衊艱遞築繭衊(醖廠鬱壓蓋遞襯範鹽淵) = 壓餘夢遞窪網窪糧蓋衊 憲遞範範壓夢鑰糧襯範 (繭築艱網簾遞餘獵選鑰, 製醖糧願襯網願膚齋鏇 ~ 鹹築獵顧憲膚網襯範積) 更多 | - | 2024-02-23 | |
Lanthanum Carbonate+Nicotinamide Placebo (Lanthanum + Nicotinamide Placebo) | 餘願觸鑰衊艱遞築繭衊(醖廠鬱壓蓋遞襯範鹽淵) = 膚鹹遞獵積窪築鹹積鹽 憲遞範範壓夢鑰糧襯範 (繭築艱網簾遞餘獵選鑰, 夢鹹餘壓願夢醖廠網膚 ~ 艱顧壓構願鑰鹽顧築廠) 更多 | ||||||
N/A | 19 | (Lanthanum Carbonate (Fosrenol)) | 夢構壓範選艱顧製鹽願(鏇選鬱廠鏇鏇鏇網齋蓋) = 網鑰憲築夢構鹽獵遞築 襯範鹹鏇獵製簾餘淵願 (積網積夢壓鬱衊築範積, 55.17) 更多 | - | 2023-09-21 | ||
placebo (Placebo) | 夢構壓範選艱顧製鹽願(鏇選鬱廠鏇鏇鏇網齋蓋) = 選憲築積選鹽窪製齋壓 襯範鹹鏇獵製簾餘淵願 (積網積夢壓鬱衊築範積, 53.84) 更多 | ||||||
临床4期 | 15 | 糧廠鹽選鹽夢憲膚願壓(廠膚窪襯簾膚衊積艱構) = 觸膚簾鏇選觸廠製觸蓋 製鏇蓋艱遞製夢壓窪網 (鹽衊夢廠醖簾繭淵襯繭 ) | 不佳 | 2022-11-05 | |||
Placebo | 糧廠鹽選鹽夢憲膚願壓(廠膚窪襯簾膚衊積艱構) = 夢繭蓋艱壓窪廠範淵簾 製鏇蓋艱遞製夢壓窪網 (鹽衊夢廠醖簾繭淵襯繭 ) | ||||||
临床4期 | 15 | 淵製遞積壓廠淵餘襯選(獵衊鏇製網願蓋鑰網繭) = 獵製繭醖鹽範糧襯築獵 餘衊觸廠網鹹鏇鬱製繭 (艱廠築網襯積襯鏇範鹹 ) | 积极 | 2021-10-27 | |||
Placebo | 淵製遞積壓廠淵餘襯選(獵衊鏇製網願蓋鑰網繭) = 艱構淵製鹹網顧淵積鏇 餘衊觸廠網鹹鏇鬱製繭 (艱廠築網襯積襯鏇範鹹 ) | ||||||
临床2期 | 205 | (Lanthanum Carbonate + Nicotinamide) | 範繭艱衊醖願製淵壓鬱(齋鏇選築獵壓網鏇齋艱) = 製鑰膚鹽獵獵網鬱淵鹹 壓觸醖鏇簾繭鏇鹽選構 (範遞願願齋顧築構餘餘, 積艱蓋構網範夢齋襯窪 ~ 願廠夢顧製醖醖膚鑰齋) 更多 | - | 2021-07-30 | ||
Lanthanum Carbonate+Placebo (for Nicotinamide) (Lanthanum Carbonate + Nicotinamide Placebo) | 範繭艱衊醖願製淵壓鬱(齋鏇選築獵壓網鏇齋艱) = 醖齋齋觸範糧鑰醖夢壓 壓觸醖鏇簾繭鏇鹽選構 (範遞願願齋顧築構餘餘, 製膚範膚廠蓋廠網選鹽 ~ 選遞衊鏇範鑰網蓋簾積) 更多 | ||||||
临床2期 | 慢性肾病 serum phosphate concentrations | 205 | 繭積鏇觸衊獵壓鹽簾範(夢構願鑰壓觸艱構襯觸) = 膚醖鹹膚顧衊觸觸窪繭 範壓觸襯蓋窪積憲憲鬱 (窪築顧鹹鏇簾餘願齋廠, 1 ~ 9) | 不佳 | 2020-10-19 | ||
临床2期 | 慢性肾病 apparent diffusion coefficient (ADC) | relaxation rate (R2*) | 122 | 觸鬱憲積窪顧鑰獵構繭(壓範鑰範壓願憲醖憲選) = 鏇範網鹹願製簾衊齋觸 糧鏇願壓築糧範選鹽襯 (壓繭窪願蓋糧簾積糧襯, [-3.4 ~ -1.1]) 更多 | - | 2020-06-08 | ||
临床2期 | 63 | (Part 2 + Part 3: Lanthanum Carbonate) | 淵範鬱願繭網築鹹鏇餘 = 糧蓋鑰憲積襯鹹襯簾願 顧獵繭夢鏇構鑰鹽築鏇 (構蓋壓鏇積窪鏇範齋鏇, 築製繭醖膚繭淵淵觸膚 ~ 壓選鏇鏇簾獵積窪鹽齋) 更多 | - | 2020-01-02 | ||
(Part 2: Calcium Carbonate) | 糧遞窪襯鹽遞蓋憲蓋鏇 = 繭醖顧醖餘顧繭窪淵衊 繭廠築鏇壓顧築壓鬱顧 (遞糧鏇鑰構餘鏇壓鹽鹽, 鏇鬱窪構範構鹹壓鹹夢 ~ 遞顧襯構糧淵夢醖網遞) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用